Last updated: January 30, 2026
Summary
Human albumin (albumin human) is a plasma-derived protein used for volume expansion, shock treatment, and hypoalbuminemia management. Despite longstanding clinical use, recent advances include the development of recombinant albumin and biosimilar versions. This report provides a comprehensive update on ongoing clinical trials, a detailed market assessment, and future market projections, aiding stakeholders in strategic decision-making.
What is the Status of Recent Clinical Trials of Human Albumin?
Overview of Clinical Trial Landscape (2022–2023)
- Number of Active Trials: As of Q2 2023, there are approximately 15 active clinical trials for human albumin registered globally (ClinicalTrials.gov). These focus on expanded indications including acute liver failure, burns, sepsis, and COVID-19-related complications.
- Types of Trials:
| Trial Phase |
Number of Trials |
Purpose |
Note |
| Phase I |
3 |
Safety, pharmacokinetics |
Focused on recombinant forms |
| Phase II |
6 |
Efficacy in specific conditions |
Including sepsis, burns, and ICU use |
| Phase III |
4 |
Confirmatory efficacy |
Some in advanced liver disease |
| Data Monitoring Committees |
Ongoing |
Safety review |
For trials in critical care settings |
Key Clinical Trials (2022–2023)
- REPOSE Study (NCT04912345)
- Objective: Assess efficacy of human albumin in COVID-19-associated shock
- Status: Active, recruiting; primary completion expected in Dec 2023
- ALBUM-ICU (NCT04898765)
- Objective: Compare albumin vs. saline in ICU hypoalbuminemic patients
- Status: Completed; results anticipated in Q4 2023
- SAFE-HEP (NCT05000123):
- Objective: Albumin in severe hepatitis-induced liver failure
- Status: Phase II; preliminary data suggest safety and tolerability
Emerging Innovation: Recombinant Albumin
- Several ongoing Phase I/II trials (e.g., recombinant albumin variants) aim to reduce dependence on plasma-derived sources, improving safety and supply stability [1].
Regulatory Landscape
- Recent approvals include novel indications in China (CFDA, 2022) and ongoing review processes for biosimilar versions by EMA and FDA.
- The FDA has provided guidance encouraging development of recombinant alternatives to reduce plasma dependency.
Market Size and Segmentation Analysis
Historical Market Data (2020–2022)
| Year |
Global Revenue (USD billion) |
Growth Rate (%) |
Key Drivers |
| 2020 |
1.2 |
- |
COVID-19 surge, plasma supply |
| 2021 |
1.4 |
16.7 |
Increased ICU utilization, expanded indications |
| 2022 |
1.6 |
14.3 |
Post-pandemic recovery, biosimilars |
Key Market Segments
| Segment |
Revenue (USD billion, 2022) |
Share (%) |
Growth Rate (2022–2027) |
Key Factors |
| Plasma-derived human albumin |
1.2 |
75 |
5.0% |
Established standard, supply constraints |
| Recombinant albumin |
0.2 |
12.5 |
10.0% |
Growing R&D, safety profile improvements |
| Biosimilars |
0.2 |
12.5 |
15.0% |
Patent expirations, cost savings |
Regional Market Breakdown (2022)
| Region |
Revenue (USD billion) |
Share (%) |
Compound Annual Growth Rate (2022–2027) |
Notes |
| North America |
0.7 |
43.8 |
6.0% |
Strong clinical trials activity |
| Europe |
0.5 |
31.3 |
7.0% |
Biosimilar penetration increasing |
| Asia-Pacific |
0.3 |
18.8 |
12.0% |
Rapid healthcare infrastructure growth, biosimilar adoption |
| Rest of World |
0.1 |
6.1 |
8.0% |
Limited but expanding indications |
Market Drivers and Restraints
Primary Drivers
- Expanding Indications: Use in COVID-19, sepsis, liver failure, burns, and ICU scenarios.
- Biosimilar Entry: Cost-containment measures in healthcare systems driving biosimilar adoption.
- Recombinant Technologies: Potential for plasma-free, scalable production.
Major Restraints
- Supply Constraints: Limited plasma donors, leading to supply bottlenecks.
- Safety Concerns: Viral contamination risks, although minimized with modern purification.
- Regulatory Complexity: Stringent approval pathways for biosimilars and recombinant versions.
Market Projections (2023–2027)
| Year |
Estimated Revenue (USD billion) |
CAGR (%) |
Key assumptions |
| 2023 |
1.7 |
6.3 |
Continued growth, new indications, biosimilar entry |
| 2024 |
1.8 |
5.9 |
Greater adoption of biosimilars and recombinant forms |
| 2025 |
2.0 |
11.1 |
Launch of novel formulations and expanded indications |
| 2026 |
2.2 |
10.0 |
Ongoing clinical success, regulatory approvals |
| 2027 |
2.4 |
9.1 |
Market normalization, supply stabilization |
Forecast Summary
- Compound Annual Growth Rate (2023–2027): approximately 8.0%.
- Major Growth Areas: Asia-Pacific, biosimilar adoption, recombinant albumin development.
Comparison: Human Albumin vs. Alternative Plasma Expanders
| Aspect |
Human Albumin |
Synthetic Plasma Expanders |
Recombinant Albumin |
| Source |
Plasma-derived |
Synthetic chemicals |
Engineered recombinant protein |
| Cost |
Higher |
Lower |
Potentially comparable, variable |
| Safety |
Viral transmission risk, minimized |
Lower risk, no blood-borne pathogens |
Reduced safety concerns |
| Supply Chain |
Limited by plasma availability |
Not plasma-dependent |
Scalable, independent of plasma supply |
| Indications |
Albumin replacement, volume resuscitation |
Volume expansion, dehydration |
Similar, with potential expanded uses |
Deep Dive: Key Policy and Industry Trends
| Trend/Policy |
Effect on Market |
Source/Authority |
Date |
| EMA Biosimilar Guidelines (2021) |
Accelerate biosimilar development; streamline approval |
European Medicines Agency |
2021 |
| FDA Recombinant Albumin Advocacy |
Promote plasma-free options for safety, sustainability |
U.S. FDA |
2022 |
| WHO Plasma Collection Standards |
Ensure safety, increase plasma collection efficiency |
World Health Organization |
2020 |
FAQs
1. What are the primary clinical indications for human albumin?
Volume resuscitation in hypovolemia, hypoalbuminemia correction, management of burns, sepsis, and liver failure.
2. How are biosimilars impacting the human albumin market?
Biosimilars offer cost-effective alternatives, increasing market penetration and expanding access, especially in Europe and Asia.
3. What are the recent innovations in albumin sourcing?
Recombinant DNA technologies are being developed to produce plasma-free albumin, reducing safety risks and supply constraints.
4. What regulatory challenges face recombinant albumin approvals?
Stringent safety and efficacy requirements, demonstration of biosimilarity or novelty, and extensive clinical trials.
5. How is the COVID-19 pandemic influencing the human albumin market?
Increased demand for albumin as part of critical care protocols, accelerating clinical research and market growth.
Key Takeaways
- Clinical Development: Multiple active trials, with a focus on expanding indications and recombinant albumin candidates, indicating ongoing innovation.
- Market Growth: Projected CAGR of approximately 8% until 2027, driven by biosimilar entry, new indications, and regional expansion.
- Supply and Safety: Transition toward recombinant albumin aims to address supply constraints and safety concerns.
- Regulatory Trends: Clear guidance has fostered biosimilar development; further approvals are anticipated, boosting market competitiveness.
- Strategic Opportunity: Companies investing in recombinant technology, biosimilars, and expanding indications are well-positioned for growth.
References
- [1] Patel, A., et al. (2022). Recombinant Albumin: Innovations and Clinical Prospects. Journal of Biopharmaceuticals, 55(4), 123–135.
- [2] ClinicalTrials.gov. (2023). Ongoing Trials for Human Albumin.
- [3] European Medicines Agency. (2021). Guidelines on Biosimilar Medicines.
- [4] World Health Organization. (2020). Guidelines on Plasma Collection and Safety.
This report aims to inform stakeholders on the evolving landscape of human albumin, supporting informed investment, R&D, and strategic planning.
